COSMOS Pharmaceutical Corporation
TSE:3349.T
9012 (JPY) • At close September 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue
| 1,011,390 | 964,989 | 827,697 | 755,414 | 726,424 |
| Cost of Revenue
| 798,109 | 776,683 | 658,979 | 603,966 | 581,313 |
| Gross Profit
| 213,281 | 188,306 | 168,718 | 151,448 | 145,111 |
| Gross Profit Ratio
| 0.211 | 0.195 | 0.204 | 0.2 | 0.2 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 107 | 116 | 128 | 127 | 129 |
| Selling & Marketing Expenses
| 1,561 | 1,812 | 1,648 | 1,632 | 2,784 |
| SG&A
| 152,430 | 138,536 | 122,807 | 107,756 | 99,163 |
| Other Expenses
| 20,447 | 18,269 | 15,782 | 13,895 | 12,801 |
| Operating Expenses
| 172,877 | 156,805 | 138,589 | 121,651 | 111,964 |
| Operating Income
| 40,404 | 31,501 | 30,128 | 29,796 | 33,147 |
| Operating Income Ratio
| 0.04 | 0.033 | 0.036 | 0.039 | 0.046 |
| Total Other Income Expenses Net
| 1,968 | 2,218 | 2,645 | 3,252 | 5,449 |
| Income Before Tax
| 42,372 | 33,719 | 32,773 | 33,048 | 38,596 |
| Income Before Tax Ratio
| 0.042 | 0.035 | 0.04 | 0.044 | 0.053 |
| Income Tax Expense
| 11,393 | 9,265 | 8,975 | 9,892 | 11,439 |
| Net Income
| 30,978 | 24,454 | 23,797 | 23,155 | 27,156 |
| Net Income Ratio
| 0.031 | 0.025 | 0.029 | 0.031 | 0.037 |
| EPS
| 390.85 | 308.61 | 300.48 | 292.37 | 342.89 |
| EPS Diluted
| 390.85 | 308.61 | 300.48 | 292.37 | 342.89 |
| EBITDA
| 64,855 | 53,744 | 50,192 | 48,210 | 46,932 |
| EBITDA Ratio
| 0.064 | 0.056 | 0.061 | 0.064 | 0.065 |